Cargando…
SARS-CoV-2 Vaccines: Status Report
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its chall...
Autores principales: | Amanat, Fatima, Krammer, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136867/ https://www.ncbi.nlm.nih.gov/pubmed/32259480 http://dx.doi.org/10.1016/j.immuni.2020.03.007 |
Ejemplares similares
-
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
por: Amanat, Fatima, et al.
Publicado: (2021) -
Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2020) -
Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
por: Amanat, Fatima, et al.
Publicado: (2021) -
Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk
por: Fox, Alisa, et al.
Publicado: (2020) -
Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)